Literature DB >> 8929227

Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors.

S Perovic1, W E Müller.   

Abstract

In the present study is is reported that the methanolic Hypericum extract LI 160 (Jarsin 300) exerts no protective effect against N-methyl-D-aspartate (NMDA-) or gp120- (from the HIV virus) induced cytotoxicity. Moreover, it is established that Hypericum extract causes no activation of arachidonic acid release from neurons activated by gp120; hence it displays no sensitization effect on the NMDA receptor channel. The main outcome of this study is the finding that Hypericum extract causes a 50% inhibition (IC50 value) of serotonin uptake by rat synaptosomes at a concentration of 6.2 microglml. Therefore it is concluded that the antidepressant activity of Hypericum extract is due to an inhibition of serotonin uptake by postsynaptic receptors. Future studies might focus on the effect of Hypericum extract on serotonin binding to neurons, serotonin storage in granules, the rate of synthesis of serotonin, and on the activity of monoamine oxidase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8929227

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  8 in total

1.  The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.

Authors:  Barbara J Caldarone; Neil E Paterson; Jia Zhou; Daniela Brunner; Alan P Kozikowski; Koen G C Westphal; Gerdien A H Korte-Bouws; Jolanda Prins; S Mechiel Korte; Berend Olivier; Afshin Ghavami
Journal:  J Pharmacol Exp Ther       Date:  2010-09-23       Impact factor: 4.030

2.  Hyperforin, the active component of St. John's wort, induces IL-8 expression in human intestinal epithelial cells via a MAPK-dependent, NF-kappaB-independent pathway.

Authors:  Changcheng Zhou; Michelle M Tabb; Asal Sadatrafiei; Felix Grün; Aixu Sun; Bruce Blumberg
Journal:  J Clin Immunol       Date:  2004-11       Impact factor: 8.317

Review 3.  Mechanism of action of St John's wort in depression : what is known?

Authors:  Veronika Butterweck
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

4.  The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease.

Authors:  Dieter Scheller; Christoph Ullmer; Reinhard Berkels; Mirella Gwarek; Hermann Lübbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-14       Impact factor: 3.000

5.  Neurochemical binding profiles of novel indole and benzofuran MDMA analogues.

Authors:  Jakob A Shimshoni; Ilan Winkler; Ezekiel Golan; David Nutt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-20       Impact factor: 3.000

Review 6.  'Atypical' antidepressants in overdose: clinical considerations with respect to safety.

Authors:  Nicholas A Buckley; Thomas A Faunce
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298].

Authors:  Siegfried Kasper; Ion-George Anghelescu; Armin Szegedi; Angelika Dienel; Meinhard Kieser
Journal:  BMC Med       Date:  2006-06-23       Impact factor: 8.775

Review 8.  Clinical relevance of St. John's wort drug interactions revisited.

Authors:  Simon Nicolussi; Jürgen Drewe; Veronika Butterweck; Henriette E Meyer Zu Schwabedissen
Journal:  Br J Pharmacol       Date:  2020-01-17       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.